Understanding patient and physician perceptions of benign prostatic hyperplasia in Europe: The Prostate Research on Behaviour and Education (PROBE) Survey

International Journal of Clinical Practice

Volumn 62, Issue 1, 2008, Pages 18-26

  Emberton, M ^a   Marberger, M ^b   De La Rosette, J ^c  

^a INSTITUTE OF UROLOGY AND NEPHROLOGY   (United Kingdom)

^b UNIVERSITY OF VIENNA   (Austria)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; FINASTERIDE; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DIGITAL RECTAL EXAMINATION; FEAR; FRANCE; GERMANY; HEALTH BEHAVIOR; HEALTH BELIEF; HEALTH EDUCATION; HEALTH SURVEY; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; PATIENT ATTITUDE; PATIENT MONITORING; PATIENT SATISFACTION; PHYSICIAN ATTITUDE; PRESCRIPTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATE SURGERY; RISK REDUCTION; SLEEP DISORDER; SPAIN; UNITED KINGDOM; URINE RETENTION; UROLOGY;

ATTITUDE OF HEALTH PERSONNEL; ATTITUDE TO HEALTH; EUROPE; HEALTH CARE SURVEYS; HUMANS; MALE; PATIENT ACCEPTANCE OF HEALTH CARE; PATIENT PARTICIPATION; PHYSICIAN-PATIENT RELATIONS; PROFESSIONAL PRACTICE; PROSTATIC HYPERPLASIA;

EID: 37349026548     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2007.01635.x     Document Type: Article

References (16)

1. Chapple CR. BHP disease management. Introduction and concluding remarks. Eur Urol 1999 36 (Suppl. 3 1 6.
2. Fitzpatrick JM, Artibani W. Therapeutic strategies for managing BPH progression. Eur Urol Suppl 2006 5 : 997 1003.
3. Montironi R, Valli M, Fabris G. Treatment of benign prostatic hyperplasia with 5-alpha-reductase inhibitor: morphological changes in patients who fail to respond. J Clin Pathol 1996 49 : 324 8.
4. Calais Da Silva F, Marquis P, Deschaseaux P et al. Relative importance of sexuality and quality of life in patients with prostatic symptoms. Eur Urol 1997 31 : 272 80.
5. Emberton M, Martorana G. BPH: social impact and patient's perspective. Eur Urol Suppl 2006 5 : 991 6.
6. Hong SJ, Rayford W, Valiquette L, Emberton M. The importance of patient perception in the clinical assessment of benign prostatic hyperplasia and its management. BJU Int 2005 95 : 15 9.
7. Emberton M, Zinner N, Michel MC et al. Managing the progression of lower urinary tract symptoms/benign prostatic hyperplasia: therapeutic options for the man at risk. BJU Int 2007 100 : 249 53.
8. McConnell JD, Roehrborn CG, Bautista OM et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003 349 : 2387 98.
9. Roehrborn CG, Boyle P, Nickel JC et al. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002 60 : 434 41.
10. Debruyne F, Barkin J, van Erps P et al. Efficacy and safety of long-term treatment with the dual 5alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol 2004 46 : 488 95.
11. Roehrborn CG, Lukkarinen O, Mark S et al. Long-term sustained improvement in symptoms of benign prostatic hyperplasia with the dual 5alpha-reductase inhibitor dutasteride: results of 4-year studies. BJU Int 2005 96 : 572 7.
12. Kawakami J, Nickel JC. Acute urinary retention and surgery for benign prostatic hyperplasia: the patient's perspective. Can J Urol 1999 6 : 819 22.
13. Teillac P. Benign prostatic hyperplasia: patients' perception of medical treatment and their expectations: results of a French survey involving patients treated with finasteride. Therapie 2002 57 : 473 83.
14. Watson V, Ryan M, Brown CT et al. Eliciting preferences for drug treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. J Urol 2004 172 : 2321 5.
15. Kaplan S, Naslund M. Public, patient, and professional attitudes towards the diagnosis and treatment of enlarged prostate: a landmark national US survey. Int J Clin Pract 2006 60 : 1157 65.
16. Fultz NH, Burgio K, Diokno AC et al. Burden of stress urinary incontinence for community-dwelling women. Am J Obstet Gynecol 2003 189 : 1275 82.